Ironwood Pharmaceuticals Inc/ US46333X1081 /
| 2024-06-14 10:00:00 PM | Chg. -0.1500 | Volume | Bid1:29:52 AM | Ask1:29:52 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 5.8300USD | -2.51% | 2.35 mill. Turnover: 10.41 mill. |
5.5200Bid Size: 300 | 6.0400Ask Size: 100 | 926.72 mill.USD | - | - |
Assets
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 17.2700 | 12.4290 | 8.9290 | 7.5750 | 6.2880 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | 65.6150 | 95.8960 | 63.3990 | 381.7020 | 319.8930 | ||||||
| Inventories | - | .6480 | - | - | - | ||||||
| Accounts Receivable | 20.9910 | 11.2790 | 122.3510 | 114.0420 | 115.4580 | ||||||
| Cash and Cash Equivalents | 173.1720 | 177.0230 | 362.5640 | 620.1290 | 656.2030 | ||||||
| Current Assets | 266.4350 | 306.8520 | 495.8390 | 745.2250 | 780.6260 | ||||||
| Total Assets | 332.0500 | 402.7480 | 559.2380 | 1,126.9270 | 1,100.5190 | ||||||
Liabilities
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 18.1230 | 3.9780 | .6610 | .9350 | .4830 | ||||||
| Long-term debt | 265.6010 | 407.9940 | 430.2560 | 337.3330 | 396.2510 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 528.4210 | 495.9990 | 496.5980 | 521.0160 | 448.1410 | ||||||
| Share Capital | .1540 | .1580 | .1610 | .1620 | .1540 | ||||||
| Total Equity | -196.3710 | -93.2510 | 62.6400 | 605.9110 | 652.3780 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 332.0500 | 402.7480 | 559.2380 | 1,126.9270 | 1,100.5190 | ||||||
Income Statement
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 346.6390 | 428.4130 | 389.5230 | 413.7530 | 410.5960 | ||||||
| Depreciation (total) | 8.1110 | - | - | - | - | ||||||
| Operating Result | -238.8920 | 120.1230 | 142.9400 | 232.2590 | 250.3370 | ||||||
| Interest Income | -37.7240 | -36.6020 | -29.4780 | -31.1500 | -7.5980 | ||||||
| Income Before Taxes | - | - | 108.8610 | 200.6570 | 252.4220 | ||||||
| Income Taxes | - | - | 2.6850 | 327.7910 | -77.3570 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -282.3680 | 21.5050 | 106.1760 | 528.4480 | 175.0650 | ||||||
Per Share
Cash Flow
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -70.8820 | 10.7250 | 168.8360 | 261.8950 | 273.7630 | ||||||
| Cash Flow from Investing Activities | 88.8660 | -11.1440 | -1.8420 | -.2650 | -.1360 | ||||||
| Cash Flow from Financing | 30.0720 | -1.1850 | 18.5460 | -4.5500 | -237.5530 | ||||||
| Decrease / Increase in Cash | 48.0560 | -1.6040 | 185.5400 | 257.0800 | 36.0740 | ||||||
| Employees | - | - | - | - | - | ||||||
